A chronic disease is still waiting for a medicine
Pharmaceutical companies have developed treatments for some of the rarest diseases that plague a small percentage of the population, but they have consistently failed to bring to market a drug for chronic diseases. and increasingly popular.
As biotech companies make new efforts to target liver disease called NASH, or non-alcoholic steatohepatitis, investors might interpret as reluctance after being burned several times. Take it Drug blocking which at the height of Wall Street’s excitement over NASH treatments earned as much as $462 a share. Since then, the stock has plummeted, trading now at just over $17, erasing $6 billion in market value. Biotech’s drug for NASH was rejected by the US Food and Drug Administration in 2020 over safety concerns, but the Intercept is trying again. Companies include Gilead Science, Genfit and NGM Biopharma is one of many others who have faced failure.